Health Products

All lots of JAMP-Mycophenolate 250 mg capsules recalled due to possible incorrect dose, which may pose health risks

· Published by Health Canada · Official notice

Details

Alert type: Public advisory
Category: Health products - Drugs
Product: JAMP-Mycophenolate 250 mg capsules
Issue: Health products - Product safety
What to do: If you are taking this medication, speak with your pharmacist as soon as possible. Your pharmacist will check if your product is affected by the recall and provide a replacement if needed. Continue to take your JAMP-Mycophenolate 250 mg capsules until you speak with your pharmacist, as mycophenolate is an important drug in preventing organ rejection in kidney, heart or liver transplant patients. Contact a health care professional immediately if you or someone you are caring for experiences serious side effects.
Audience: General public
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

LoDINProductExpiry
EG22MPM001
EG22PMP002
EG22MPM003
EG23MPM001
EG23MPM002
EG23MPM003
02386399JAMP-Mycophenolate 250 mg capsules2025-08
2025-08
2025-08
2026-08
2026-08
2026-08

Issue

JAMP Pharma Corporation is recalling all lots of JAMP-Mycophenolate 250 mg capsules as some capsules may weigh less or more than they should. Patients taking an overweight or underweight capsule could unexpectedly receive a higher or lower dose than intended. Mycophenolate is a drug where differences in dose can lead to very serious side effects; therefore, it is essential that patients taking an affected product return it to the pharmacy as soon as possible for replacement.

JAMP-Mycophenolate is a prescription drug used by adults and children aged two and older after an organ transplant to help prevent organ rejection. It works by reducing or suppressing the body's immune response.

Taking a lower dose of mycophenolate could reduce its effectiveness and lead to organ rejection, which is serious. This risk is especially high in the first weeks after transplantation. General signs and symptoms of organ rejection may include pain at the site of the transplant, feeling unwell, feeling tired or having no energy, flu-like symptoms, fever, sudden weight changes, swelling, change in heart rate or urinating less often.

Taking a higher dose than intended can increase the risk of side effects, including new or worsening nausea, vomiting, and/or diarrhea. In some cases, it may lead to over-suppression of the immune system and increased risk of infections. Infections in immunosuppressed patients can be fatal.

Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime